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Background: A major barrier to successful treatment in alcohol dependence is psychiatric comorbidity. During
treatment, the time to relapse is shorter, the drop-out rate is increased, and long-term alcohol consumption is
greater for those with comorbid major depression or anxiety disorder than those with an alcohol use disorder with
no comorbid mental disorder. The treatment of alcohol dependence and psychological disorders is often the
responsibility of different services, and this can hinder the treatment process. Accordingly, there is a need for an
effective integrated treatment for alcohol dependence and comorbid anxiety and/or depression.
Methods/Design: We aim to assess the effectiveness of a specialized, integrated intervention for alcohol
dependence with comorbid anxiety and/or mood disorder using a randomized design in an outpatient hospital
setting. Following a three-week stabilization period (abstinence or significantly reduced consumption), participants
will undergo complete formal assessment for anxiety and depression. Those patients with a diagnosis of an anxiety
and/or depressive disorder will be randomized to either 1) integrated intervention (cognitive behavioral therapy) for
alcohol, anxiety, and/or depression; or 2) usual counseling care for alcohol problems. Patients will then be followed
up at weeks 12, 16, and 24. The primary outcome measure is alcohol consumption (total abstinence, time to lapse,
and time to relapse). Secondary outcome measures include changes in alcohol dependence severity, depression, or
anxiety symptoms and changes in clinician-rated severity of anxiety and depression.
Discussion: The study findings will have potential implications for clinical practice by evaluating the implementation
of specialized integrated treatment for comorbid anxiety and/or depression in an alcohol outpatient service.
Trial registration: ClinicalTrials.gov Identifier: NCT01941693
Keywords: Alcohol dependence, Anxiety, Depression, Cognitive behavioral therapy, Integrated care, Randomized
controlled trialBackground
There is a high rate of psychological comorbidity in
people with alcohol dependence [1,2]. This is of concern
given that, during treatment, the time to relapse is shorter,
the drop-out rate is increased, and long-term alcohol con-
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stated.depression or anxiety disorder than for those with an alco-
hol use disorder (AUD) with no comorbid mental disorder
[3-5]. In the Australian National Survey of Mental Health
and Wellbeing, Teesson and colleagues [6] reported that
33% of more than 10,000 respondents with an AUD also
suffered from an anxiety or mood disorder as defined by
the Diagnostic and Statistical Manual of Mental Health
Disorders, 4th ed. (DSM-IV). In addition, this subpopula-
tion was significantly more disabled and used health
services more frequently than those with AUD with no
comorbid mental disorder [6]. Results from the largeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Treatment to Client Heterogeneity) highlight psychiatric
comorbidity as a significant factor influencing treatment re-
sponse for alcohol dependence [7]. Similarly, we have re-
ported that, among alcohol-dependent patients, clinically
significant levels of depression predicted poor response to
alcohol treatment [8]. Unfortunately, however, the treat-
ment of alcohol dependence and psychological disorders is
often the responsibility of different services, and this may
hinder the treatment process. Accordingly, there is a need
for an effective integrated treatment for alcohol dependence
and comorbid anxiety or depression in outpatient services.
To date, research has usually assessed different psycho-
social methods or pharmacological treatments targeted at
alcohol dependence and psychological disorders separately.
The focus has rarely been on concurrent treatment for both
conditions. Regarding alcohol dependence and comorbid
depression, there have been only two psychosocial interven-
tion trials. Brown et al. [9] observed in 35 inpatients that
adding CBT for depression versus relaxation training to
standard partial hospital alcohol treatment was more effect-
ive in reducing depressive symptoms and some drinking
outcomes than treatment for the alcohol problem only.
They also observed that decreases in somatic depressive
symptoms mediated the relationship between treatment
condition and drinking outcomes. However, in a follow-up
larger clinical trial, Brown et al. [10] found no significant
differences on alcohol use outcomes and inconsistent ef-
fects on symptoms of depression. In both these studies, the
interventions for depression and alcohol were not inte-
grated, and the alcohol psychoeducational intervention was
group-delivered only during the initial hospital stay.
There have been some studies investigating concurrent,
but not integrated, treatments for alcohol dependence and
anxiety disorders. Two studies found little beneficial effect
from concurrent treatment for alcohol dependence and
anxiety disorders (panic disorder and social phobia) [11,12].
However, in both studies, limited success may have been
due, in part, to an inability to differentiate alcohol-related
anxiety from non-alcohol–related symptoms at baseline as-
sessment. Patients were either in withdrawal or not neces-
sarily abstinent at the time of assessment, such that that
anxiety symptoms resulting from alcohol withdrawal may
have confounded the initial diagnoses. In many cases,
symptoms of depression and anxiety resolve with abstin-
ence so that further treatment is not required. However, in
other cases where abstinence is achieved, these symptoms
persist or worsen. To this degree, the stepped-care model
entails assessing the outcome of primary treatment and sys-
tematically offering a secondary treatment where indicated
and thus has the potential to provide a clearly structured,
logical, and economical treatment [13-15].
More recently, Schadé et al. [16] trialed an intensive 32-
week psychosocial and disulfiram treatment interventionfor alcohol, either alone or in combination with CBT and
optional pharmacotherapy for anxiety, among abstinent
alcohol-dependent patients with comorbid social phobia
or agoraphobia. They found that additional therapy for
anxiety significantly reduced anxiety symptoms and avoid-
ance behavior but did not affect alcohol relapse rates.
With regard to post-traumatic stress disorder (PTSD),
while reductions in alcohol consumption have report-
edly mediated PTSD responsiveness [17], early improve-
ment in PTSD symptoms appears to have a greater impact
on improvement in alcohol dependence than the recipro-
cal relationship, which has prompted recommendations
for integrated treatment [18]. To this degree, Mills et al.
[19] examined integrated prolonged exposure treatment
versus usual care for comorbid PTSD and substance de-
pendence and observed a reduction in PTSD severity but
no group differences in changes to substance use, de-
pression, or anxiety. Sannibale et al. [20] recently inves-
tigated whether combining existing CBT interventions
for AUD and PTSD would produce better outcomes than
treating AUD alone. Although large overall reductions in
PTSD and alcohol-related outcomes were found between
groups, secondary analyses revealed a two-fold greater
clinically significant change in PTSD severity for integrated
therapy participants who attended one or more sessions
of exposure therapy relative to participants treated for
AUD alone.
Interestingly, Brown et al. [9,10] observed changes in
the benefit of CBT for depression across two trials de-
pending on the treatment context: they observed that
CBT was more effective relative to a relaxation control
when given separately with CBT for alcohol dependence
in an inpatient versus an outpatient setting. The authors
concluded that a synergistic beneficial treatment effect
occurred in the inpatient setting due to CBT for depres-
sion being concurrently provided with CBT for alcohol
dependence, albeit delivered by separate clinicians. This
suggests the need to test the effectiveness of integrated
interventions in specific service-delivery contexts.
One difficulty in devising integrated treatment for comor-
bid disorders is the limited research identifying reciprocal
relationships between the disorders and the processes that
may underlie these relationships. A number of processes
have been proposed to underlie comorbidity between anx-
iety, depression, and alcohol dependence including 1) “self-
medicating” a mood or anxiety disorder with alcohol
[21,22], 2) the arousing and depressant properties of alcohol
causing symptoms similar to anxiety and depression, and 3)
trait-like factors such as anxiety sensitivity leading to poorly
tolerated withdrawal [23,24]. Targeting specific mechanisms
that may underlie comorbidity during treatment is likely to
be a productive strategy.
We developed an integrated treatment for alcohol de-
pendence and comorbid anxiety and/or mood disorder to
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delivery setting. The specific aims of this study are 1) to
assess the effectiveness of an integrated intervention com-
pared with usual care at reducing alcohol consumption
and anxiety and depression symptoms among alcohol-
dependent patients with comorbid anxiety and/or depres-
sion in an outpatient hospital setting; 2) to determine
factors that mediate the relationship between treatment
condition and drinking and/or mood outcomes, and 3)
to describe important factors relating to the maintenance
of alcohol-related psychiatric comorbidity. This study de-
sign will draw on the stepped-care approach to inter-
ventions for alcohol dependence [14,15] and apply this
approach to comorbid anxiety and depression by providing
additional care for a second diagnosis when that diagnosis
becomes clear. Hence, alcohol-dependent outpatients will
undergo a stabilization period from alcohol followed by a
formal assessment for diagnosis of anxiety and/or depres-
sion before being randomly allocated to receive either
usual or integrated care.
Methods
Procedure
The flow of participants is outlined in Figure 1. The first
phase of the study is to establish a stabilization period from
alcohol for three weeks before entering the randomization
step of the study. During the stabilization period, partici-
pants will have the option of pharmacotherapy using nal-
trexone (50 mg, 1 tablet daily), acamprosate (333 mg, 2
tablets 3 times daily, reduced to 4 per day for women
weighing < 65 kg), or a combination of the two as medic-
ally prescribed based on physician judgment and partici-
pant preference. After a three- to four-week stabilization
period, patients will undergo complete formal assessment
for anxiety and depression. Those with a diagnosis of anx-
iety or depressive disorder, regardless of drinking outcome,
will be offered the next step of care. The remaining partici-
pants will be monitored for a further nine weeks while re-
ceiving alcohol pharmacotherapy and/or usual counseling
care. Patients to undergo the next phase will also continue
to receive further alcohol pharmacotherapy as medically
prescribed but will be randomized to one of two treatment
groups: 1) integrated intervention for comorbid alcohol,
anxiety, and/or depression, or 2) usual counseling care.
Follow-up appointments will then be scheduled at weeks
12, 16, and 24 as described below.
Participants
A total of 100 patients will be recruited from inpatients and
outpatients of participating hospitals via flyers and commu-
nity advertisements at local general practice offices, in
newspapers, and on the Sydney Alcohol Treatment Group
website. Conservatively assuming that 40% of respondents
will not be eligible for randomization at step 2 followingdiagnosis for depression or anxiety disorder, we anticipate
that 60 patients will be randomized to one of the two
groups. Participant time and travel expenses will be reim-
bursed at follow-up assessments. The trial will be con-
ducted at the Drug Health Services outpatient clinic of the
Royal Prince Alfred Hospital, NSW, Australia. Ethics ap-
proval for the study has been granted by The Sydney Local
Health District Ethics Review Committee (X05-0275).
Randomization and allocation concealment
Randomization will be stratified according to concomitant
selective serotonin reuptake inhibitor (SSRI) use and will
by referring to the consecutively assigned subject identifi-
cation number to a matched numbered envelope contain-
ing a random assignment card. Assessors will be blind to
treatment allocation for the follow-up diagnostic inter-
views, and the same assessor will not assess the participant
they assessed at baseline. Participants were asked not to
mention their therapist or details of their therapy during
their follow-up assessment. In order to evaluate the blind-
ing process, assessors will be asked to which treatment
group they believe each participant was allocated. A paper
wall will be implemented whereby the researchers that ob-
tain follow-up data will have no knowledge of treatment-
group allocation.
Step 1: inclusion and exclusion criteria for study enrollment
Inclusion criteria are as follows: alcohol dependence ac-
cording to DSM-IV criteria, with alcohol as the subject’s
drug of choice; age 18–65; adequate cognition and English-
language skills to give valid consent and complete research
interviews as assessed by the Mini Mental State Examin-
ation (MMSE); willingness to give written consent; abstin-
ence from alcohol for between three and 21 days (standard
clinical criteria for use of acamprosate or naltrexone); reso-
lution of any clinically evident alcohol withdrawal as mea-
sured by the Clinical Institute Withdrawal Assessment for
Alcohol–Revised (CIWA-Ar) [25]; and a positive score on
the initial Comorbidity Suspicion Checklist (CSC). The
CSC is a brief assessment to be administered at the first
appointment. It is comprised of a one-page checklist to be
filled in by one of the assessing clinicians to screen for
current anxiety/depressive symptoms, previous diagnoses
of comorbid conditions (anxiety disorder or depression), a
previous history of treatment for comorbid conditions
(anxiety disorder or depression), and a positive score on
either the Mini Social Phobia Inventory (Mini-SPIN) for
social anxiety [26] or the Kessler Psychological Distress
Scale (K10) measure of psychological distress [27] for anx-
iety and depression.
Exclusion criteria include active major psychiatric dis-
order associated with significant suicide risk, pregnancy
or lactation, advanced liver disease (hepatocellular fail-
ure, variceal bleeding, ascites, or encephalopathy), or
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Figure 1 Flowchart of participants through the trial.
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adherence to the study protocol.
Step 2: inclusion and exclusion criteria for randomization
Inclusion criteria for randomization include abstinence
and/or clinically significant reduction in alcohol use per
clinician judgment, resolution of any clinically evidentalcohol withdrawal as indicated by CIWA-Ar results, and
case formulation and diagnosis for anxiety or depression.
Exclusion criteria include alcohol consumption at baseline
levels and resolution of clinically evident anxiety or depres-
sion as assessed by the case formulation (see below). These
patients will be offered further treatment as appropriate
within the service and will continue to be monitored.
Table 1 Cognitive behavioral therapy manuals forming
the basis of integrated care for depression, anxiety, and
alcohol use disorders
Diagnosis Manual
Depression Persons et al. [43]
Social phobia Rapee [44] Rapee & Sanderson [45]
Panic disorder or agoraphobia Andrews et al. [46]
Generalized anxiety disorder Andrews et al. [47]
Post-traumatic stress disorder Foa & Rothbaum [48], Najavits [49]
Alcohol use disorders Monti et al. [41] Miller et al. [42]
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Baseline assessment
Baseline assessment will be of 40 minutes’ duration and
will be conducted upon consent to enter the trial. Data
will be gathered on demographics, long-term alcohol con-
sumption, medical history of alcohol- and nonalcohol-
related illness, drug abuse, age of onset, and family
history of alcohol problems. Recent (past 30-day) alcohol
consumption will also be assessed by the timeline follow-
back (TLFB) method [28]. Severity of dependence will
be assessed by the Obsessive-Compulsive Drinking Scale
(OCDS) [29] and by the Alcohol Dependence Scale (ADS)
[30]. Functional disability will be assessed by the Short-
Form Health Survey (SF-12) [31]. Depression, anxiety, and
stress levels will be measured by the Depression Anxiety
Stress Scales (DASS) [32]. Motivation to change and per-
ceived self-efficacy are likely to vary between individuals
and be a determinant of treatment outcome; therefore,
these will be assessed by the Stages of Change Readiness
and Treatment Eagerness (SOCRATES) Scale [33] and the
Alcohol Abstinence Self-Efficacy (AASE) Scale [34]. Sleep
disturbance will be assessed by the Insomnia Severity
Index (ISI) [35], and the psychological basis of insomnia
will be assessed by the Glasgow Sleep Effort (GSES) Scale.
History of other drug use will be determined by the Opi-
ate Treatment Index (OTI) interviewer-conducted ques-
tionnaire. Blood samples will be taken for full blood count
and liver function tests.
Formal diagnosis of comorbid anxiety or depression
(stepped-care assessment)
Several additional indices will be assessed at the com-
mencement of the stepped-care phase:
 Interview measures: Recent (past 30-day) alcohol
consumption will be available from the drinking
diary cards offered upon entry to the trial. Diagnoses
of anxiety and affective disorders will be established
by the Anxiety Disorders Interview Schedule (ADIS)
for DSM-IV [36]. The structured interview for the
Hamilton Rating Scale for Depression (HRSD) will
be used to measure the severity of depressive
disorders [37]. The International Personality
Disorder Examination [38] will be used to screen for
personality disorders.
 Questionnaire measures: Continuous measures of
change for anxiety or depression will be obtained by
administering the DASS [32]. Recent severity of
alcohol dependence will be assessed by the OCDS
and by the ADS [30]. Functional disability will be
assessed by the SF-12 [31]. Information from all
sources will be integrated into a case formulation
following methods described by Persons and
Tompkins [39].Follow-up schedule and assessments
Brief reviews will be scheduled with clinic medical staff
at weeks 1, 6, 12, 16, and 24. Clinical and psychosocial
events related to alcohol will be recorded along with ser-
ial liver function tests and mean corpuscular volume at
baseline and at 6, 12, 16, and 24 weeks. At weeks 12, 16,
and 24, the following research instruments will be admin-
istered as described above: DASS, ADS, SF-12, OCDS,
GSES, ISI, AASE, SOCRATES, OTI, and a TLFB. At week
16, sections of diagnostic interviews relevant to diagnoses
established at randomization (entry to step 2) will be read-
ministered by a blind assessor. Recent alcohol consump-
tion will be assessed as above and with a daily diary.
Throughout the trial, any adverse and serious adverse
events will be recorded. Participants will provide informa-
tion concerning at least two contacts and receive three at-




Counseling for the treatment of alcohol dependence will
continue in accordance with standard practice at the
participating treatment site [40]. This entails brief indi-
vidualized motivation enhancement therapy (ie, feedback
of assessment findings, reinforcement, empathy, enhan-
cing client’s own motivation). Participation in treatment
sessions will be recorded. As quality-control measures,
counselors will be supervised by senior staff and engage
in weekly meetings, and treatment will be delivered ac-
cording to the evidence-based treatment manual of Jarvis
et al. [40].
Intervention for alcohol and comorbid anxiety and/or
mood disorder
Structured interviews will be audiotaped and reviewed
by the clinical team to develop consensus case formula-
tions. Trained therapists will deliver specific CBT inter-
ventions based on evidence-based treatment manuals for
alcohol use, anxiety, and depressive disorders (Table 1).
Cognitive restructuring and graded exposure or behav-
ioral experiments are techniques that are common to
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structuring involves helping patients identify the key be-
liefs they hold about themselves, the future, the outside
world, and other people that maintain their drinking,
anxiety, or depression and assisting them to dispute and
develop more helpful alternative beliefs. Graded expos-
ure and behavioral experiments involve the gradual and
programmed confronting of feared situations and has
been argued to be the single most successful technique
for overcoming phobias. These are necessarily brief de-
scriptions for therapy that are well-documented in the
treatment manuals displayed in Table 1. These manuals
will be adapted for use with an alcohol-dependent popula-
tion, and cognitive-behavioral coping skills and motiv-
ational enhancement strategies for alcohol consumption
will be used where appropriate [41,42]. We expect differ-
ent and complex interactions between the comorbid dis-
orders, because the patients targeted for this study will
experience significant comorbidity. An individualized case
formulation, which hypothesizes the factors that maintain
each individual’s problems, will be constructed following
assessment using standard methods [39] (Table 2). The in-
terventions will be delivered in seven to 10 sessions. ToTable 2 Schedule of assessments
Measure Schedule









DSM-IV assessed dependence Baseline (step 1)
Alcohol Dependence Scale (ADS) Baseline (step 1), Weeks 12, 16, 24
Obsessive Compulsive Drinking
Scale (OCDS)
Baseline (step 1), Weeks 12, 16, 24
Stages of Change Readiness and
Treatment Eagerness
(SOCRATES) Scale
Baseline (step 1), Weeks 12, 16, 24
Alcohol Abstinence
Self-Efficacy (AASE)
Baseline (step 1), Week 12, 16, 24
Short-Form Health Survey (SF-12) Baseline (step 1), Week 12, 16, 24
Depression Anxiety Stress
Scale (DASS)
Baseline, Week 3 (step 2**), 12, 16, 24
Insomnia Severity Index (ISI) Baseline, Week 3 (step 2), 12, 16, 24
Glasgow Sleep Effort
Scale (GSES)
Baseline, Week 3 (step 2), 12, 16, 24
Timeline Follow-back (TLFB) Baseline, Week 3 (step 2), 12, 16, 24
Anxiety Disorders Interview
Schedule (ADIS)
Week 3 (step 2), Week 16
Hamilton Rating Scale for
Depression (HRSD)
Week 3 (step 2), Week 16
*Step 1 = week 0 preceding three-week alcohol stabilization phase.
**Step 2 = formal diagnosis for depression and/or anxiety disorder preceding
randomization to usual care or integrated care.ensure that therapists adopt and maintain the principles
of the therapy as described in the manual, sessions with
consenting subjects will be audiotaped for discussion with
the therapist early in the study (n = 4 per therapist) and at
random times later in the study (n = 4 per therapist).
Outcome measures
Primary outcomes include time to consumption of any
alcohol (lapse) as identified by self-reported alcohol con-
sumption; time to relapse as ≥ 4 drinks for women, ≥ 6
drinks for men; amount of alcohol consumed (total ab-
stinence and average consumption per drinking day).
Secondary outcomes include improvement in depressive
or anxiety symptoms (DASS) or alcohol dependence se-
verity (ADS); biological markers of alcohol consumption
at 6, 12, 16, and 24 weeks (carbohydrate-deficient transfer-
rin, liver function, and mean corpuscular volume); epi-
sodes of alcohol-related harm (psychosocial, occupational,
forensic, medical); and clinician-rated severity of anxiety
and depression based on ADIS and HRSD.
Statistical analysis
The modified intention-to-treat principle will be used such
that all subjects who attend the first intervention session
will be analyzed [50]. The success of randomization will be
tested by comparing baseline characteristics of the study
groups with potentially confounding variables included as
covariables. Analysis of variance will be used to compare
continuous variables. Categorical variables will be com-
pared via chi-square test. The effect of treatment on time-
related outcome measures such as lapse and relapse will
be analyzed by life-table survival analysis. Binary linear gen-
eralized estimating equations (GEE), with autoregressive
correlation matrices, will be employed to determine differ-
ences between integrated care and usual care groups on
change in anxiety or mood symptoms. A series of regres-
sion analyses will be performed to assess the role of symp-
tomatic change in alcohol consumption and vice versa.
Last-point carried forward or multiple imputation will be
used to determine the scores of participants who drop out
or are lost to follow-up. One previous study [9] with a simi-
lar design (N = 35) demonstrated that combined CBT treat-
ment of alcohol dependence and comorbid depression
significantly improved alcohol use outcomes with a moder-
ate effect size. Power analysis has thus been performed such
that a sample of 60 subjects (30 per group) has 80% power
of detecting a moderate difference between the two arms of
care on alcohol use outcomes at alpha = 0.05.
Discussion
The main aim of the current study is to assess the
effectiveness of a CBT-integrated intervention for alcohol-
dependent patients with comorbid anxiety and/or de-
pression compared with usual care in reducing alcohol
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in an outpatient hospital setting. This study has several
strengths, including a randomized controlled assessor-
blind design that attempts to address a serious gap in
the treatment evidence. However, one challenge may in-
clude generalizability of the results given the specialized
integrated intervention.
In addition, the secondary aims of the study are to de-
termine factors that mediate the relationship between
treatment condition and drinking and/or mood outcomes
and to describe important factors relating to the mainten-
ance of alcohol-related psychiatric comorbidity. Targeting
specific mechanisms that may underlie comorbidity dur-
ing treatment is likely to be a productive strategy. How-
ever, a limitation of the current study may include the
capacity to document these processes and mechanisms
with adequate power.
The study findings will have potential implications for
clinical practice by evaluating the implementation of spe-
cialized integrated treatment for comorbid anxiety and/or
depression in an alcohol outpatient service. The results
may, therefore, improve treatment outcomes for people
with alcohol dependence by addressing fundamental bar-
riers to treatment response. A clearer understanding of
these issues is a prerequisite to devising and implementing
appropriate clinical interventions.
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